Published in Cancer Weekly, June 1st, 1998
Merck KGaA, Darmstadt, Germany, is ImClone's corporate partner in the development of BEC2. The Phase III trial evaluates the effect of BEC2 in approximately 800 patients with small cell lung carcinoma.
"The initiation of ImClone's first Phase III trial marks a milestone for the company," commented Harlan W. Waksal, M.D., ImClone Systems. "This is the most advanced lung cancer vaccine study and one of the largest studies of any type of cancer vaccine. We are encouraged by our results from previous tests and look...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.